HC Wainwright Issues Negative Forecast for MIST Earnings

Milestone Pharmaceuticals Inc. (NASDAQ:MIST) – HC Wainwright dropped their Q1 2025 earnings estimates for shares of Milestone Pharmaceuticals in a report released on Monday, March 17th. HC Wainwright analyst P. Trucchio now expects that the company will post earnings of ($0.18) per share for the quarter, down from their previous estimate of ($0.17). HC Wainwright currently has a “Buy” rating and a $25.00 price target on the stock. The consensus estimate for Milestone Pharmaceuticals’ current full-year earnings is ($0.62) per share. HC Wainwright also issued estimates for Milestone Pharmaceuticals’ Q2 2025 earnings at ($0.21) EPS, Q4 2025 earnings at ($0.30) EPS, FY2025 earnings at ($1.02) EPS, FY2026 earnings at ($0.89) EPS and FY2027 earnings at ($0.02) EPS.

Milestone Pharmaceuticals Trading Down 16.4 %

Shares of MIST stock opened at $1.99 on Thursday. Milestone Pharmaceuticals has a 12-month low of $1.12 and a 12-month high of $2.75. The company has a market capitalization of $106.12 million, a PE ratio of -2.46 and a beta of 1.83. The firm has a 50 day moving average price of $2.02 and a two-hundred day moving average price of $1.81. The company has a quick ratio of 15.40, a current ratio of 15.40 and a debt-to-equity ratio of 2.18.

Institutional Trading of Milestone Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in MIST. Atria Investments Inc increased its position in Milestone Pharmaceuticals by 44.4% during the 3rd quarter. Atria Investments Inc now owns 40,421 shares of the company’s stock worth $61,000 after buying an additional 12,430 shares during the period. PVG Asset Management Corp bought a new stake in Milestone Pharmaceuticals in the 3rd quarter valued at about $46,000. Jones Financial Companies Lllp increased its holdings in shares of Milestone Pharmaceuticals by 1,000.0% during the fourth quarter. Jones Financial Companies Lllp now owns 11,000 shares of the company’s stock worth $26,000 after purchasing an additional 10,000 shares during the period. Virtu Financial LLC bought a new stake in shares of Milestone Pharmaceuticals in the fourth quarter valued at approximately $170,000. Finally, National Bank of Canada FI increased its stake in Milestone Pharmaceuticals by 163.4% during the 4th quarter. National Bank of Canada FI now owns 18,700 shares of the company’s stock worth $44,000 after acquiring an additional 11,600 shares during the period. 86.18% of the stock is owned by institutional investors and hedge funds.

Milestone Pharmaceuticals Company Profile

Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.